Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte Is Maintained at Outperform by Mizuho
Vaxcyte Analyst Ratings
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
Mizuho Securities analyst Salim Syed maintains $Vaxcyte(PCVX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -6.2% over the
Vaxcyte's VAX-31 Vaccine: A Strong Buy With Increased Revenue Projections and Substantial Market Potential
Express News | Vaxcyte Inc : Mizuho Raises Target Price to $163 From $113